T1	PROC 46 67	Estudio multinacional
T2	CHEM 115 127	enzalutamida
#1	AnnotatorNotes T2	C3496793; enzalutamide; Organic Chemical · Pharmacologic Substance
T3	DISO 146 164	cáncer de próstata
#2	AnnotatorNotes T3	C0376358; Malignant neoplasm of prostate; Neoplastic Process
T4	DISO 174 184	metástasis
#3	AnnotatorNotes T4	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T5	PROC 208 339	Estudio multinacional, de fase III, aleatorizado, con doble enmascaramiento y controlado con placebo, de la eficacia y la seguridad
T6	PROC 73 108	evualuar la seguridad y efectividad
T7	PROC 672 696	consentimiento informado
#4	AnnotatorNotes T7	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T8	CHEM 346 358	enzalutamida
#5	AnnotatorNotes T8	C3496793; enzalutamide; Organic Chemical · Pharmacologic Substance
T9	DISO 380 416	cáncer de próstata no metastatizante
T10	PROC 434 444	castración
#6	AnnotatorNotes T10	C0007344; Castration; Therapeutic or Preventive Procedure
T11	DISO 469 487	Cáncer de próstata
#7	AnnotatorNotes T11	C0376358; Malignant neoplasm of prostate; Neoplastic Process
T12	DISO 528 564	cáncer de próstata no metastatizante
T13	ANAT 156 164	próstata
#8	AnnotatorNotes T13	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T14	PROC 581 591	castración
#9	AnnotatorNotes T14	C0007344; Castration; Therapeutic or Preventive Procedure
T15	DISO 755 781	adenocarcinoma de próstata
#10	AnnotatorNotes T15	C0007112; Adenocarcinoma of prostate; Neoplastic Process
T16	ANAT 390 398	próstata
#11	AnnotatorNotes T16	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T17	ANAT 844 858	neuroendocrina
#12	AnnotatorNotes T17	C0027912; Neurosecretory Systems; Body System
T18	ANAT 860 876	células en sello
T19	Observation 881 909	características microcíticas
#13	AnnotatorNotes T19	C0302870; microcytic; Finding
T20	PROC 932 968	tratamiento de deprivación andrógena
T21	PROC 1019 1041	orquiectomía bilateral
#14	AnnotatorNotes T21	C0007347; Male Castration; Therapeutic or Preventive Procedure
T22	PROC 1052 1082	castración quirúrgica o médica
T23	PROC 1282 1296	aleatorización
#15	AnnotatorNotes T23	C0034656; Randomization; Research Activity
T24	CHEM 1190 1203	bisfosfonatos
#16	AnnotatorNotes T24	C2267018; Bisphosphonate [EPC]; Pharmacologic Substance
T25	CHEM 1206 1215	denosumab
#17	AnnotatorNotes T25	C1690432; denosumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T26	DISO 1314 1335	enfermedad progresiva
T27	PROC 1340 1376	tratamiento de deprivación andrógena
T28	PROC 1433 1448	valores del PSA
T29	CHEM 1445 1448	PSA
#18	AnnotatorNotes T29	C0138741; Prostate-Specific Antigen; Amino Acid, Peptide, or Protein · Enzyme · Immunologic Factor
T30	PROC 1490 1500	evaluación
#19	AnnotatorNotes T30	C1261322; Evaluation procedure; Health Care Activity
T31	ANAT 479 487	próstata
#20	AnnotatorNotes T31	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T32	ANAT 538 546	próstata
#21	AnnotatorNotes T32	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T33	ANAT 773 781	próstata
#22	AnnotatorNotes T33	C0033572; Prostate; Body Part, Organ, or Organ Component | C1278980; Entire prostate; Body Part, Organ, or Organ Component
T34	PROC 802 812	histología
#23	AnnotatorNotes T34	C0344441; Histology Procedure; Laboratory Procedure
T35	PROC 815 824	citología
#24	AnnotatorNotes T35	C1305671; Cytology procedure; Laboratory Procedure
T36	CHEM 985 1016	agonista/antagonista de la GnRH
#25	AnnotatorNotes T36	C1518041; Luteinizing Hormone-releasing Hormone Agonist; Pharmacologic Substance + C1268855; Gonadotropin releasing hormone antagonist; Hormone · Pharmacologic Substance
T37	PROC 1087 1099	Testosterona
#26	AnnotatorNotes T37	C0523912; Testosterone measurement; Laboratory Procedure
T38	PROC 1527 1530	PSA
#27	AnnotatorNotes T38	C0201544; Prostate specific antigen measurement; Laboratory Procedure
T39	Date 13 17	2012
T40	LIVB 131 140	pacientes
#28	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T41	Neg_cue 165 167	no
T42	LIVB 366 375	pacientes
#29	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group
T44	LIVB 514 523	pacientes
#30	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group
T46	Age 626 639	18 años o más
T47	Neg_cue 825 828	sin
T49	Neg_cue 878 880	ni
T50	LIVB 1168 1177	pacientes
#31	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	Duration 1251 1269	al menos 4 semanas
T52	Duration 1559 1569	≥ 1 semana
T43	Dose 1220 1225;1235 1242	dosis estable
T45	Date 969 977	en curso
A1	Assertion T4 Negated
A2	Assertion T18 Negated
A3	Assertion T19 Negated
A4	Status T21 History_of
#33	AnnotatorNotes T5	C1096776; Multicenter Study; Research Activity + C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product + C0511730; Identify product efficacy and safety issues; Health Care Activity
#34	AnnotatorNotes T9	C4759295; Non-metastatic prostate cancer; Neoplastic Process 
#35	AnnotatorNotes T12	C4759295; Non-metastatic prostate cancer; Neoplastic Process 
#36	AnnotatorNotes T20	C0279492; Antiandrogen therapy; Therapeutic or Preventive Procedure 
#37	AnnotatorNotes T26	C1335499; Progressive Disease; Disease or Syndrome 
#38	AnnotatorNotes T27	C0279492; Antiandrogen therapy; Therapeutic or Preventive Procedure
#39	AnnotatorNotes T28	C0201544; Prostate specific antigen measurement; Laboratory Procedure
T48	Observation 829 858	diferenciación neuroendocrina
A5	Assertion T48 Negated
#40	AnnotatorNotes T48	C1709218; Neuroendocrine Differentiation; Finding
R1	Negation Arg1:T47 Arg2:T48	
R2	Negation Arg1:T47 Arg2:T18	
R3	Negation Arg1:T49 Arg2:T19	
T53	Neg_cue 399 401	no
T54	Quantifier_or_Qualifier 402 416	metastatizante
A6	Assertion T54 Negated
#41	AnnotatorNotes T54	C1522484; metastatic qualifier; Functional Concept | C0036525; Metastatic to; Functional Concept
R4	Negation Arg1:T53 Arg2:T54	
R5	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T54	
T55	Neg_cue 547 549	no
T56	Quantifier_or_Qualifier 550 564	metastatizante
A7	Assertion T56 Negated
#42	AnnotatorNotes T56	C1522484; metastatic qualifier; Functional Concept | C0036525; Metastatic to; Functional Concept
R6	Negation Arg1:T55 Arg2:T56	
R7	Negation Arg1:T41 Arg2:T4	
#43	AnnotatorNotes T18	C0333727; Signet ring cell; Cell
R8	Location_of Arg1:T33 Arg2:T15	
R11	Location_of Arg1:T32 Arg2:T12	
R12	Location_of Arg1:T31 Arg2:T11	
R13	Location_of Arg1:T16 Arg2:T9	
R14	Before Arg1:T3 Arg2:T4	
R15	Location_of Arg1:T13 Arg2:T3	
R16	Experiences Arg1:T40 Arg2:T3	
R17	Experiences Arg1:T40 Arg2:T2	
R18	Experiences Arg1:T40 Arg2:T4	
R19	Experiences Arg1:T42 Arg2:T8	
R20	Experiences Arg1:T42 Arg2:T9	
R21	Experiences Arg1:T42 Arg2:T10	
T57	Observation 418 444	resistente a la castración
#44	AnnotatorNotes T57	C4329620; Castration Resistance; Finding
R22	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T57	
T58	Observation 565 591	resistente a la castración
#45	AnnotatorNotes T58	C4329620; Castration Resistance; Finding
R23	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T58	
R24	Experiences Arg1:T44 Arg2:T12	
R25	Experiences Arg1:T44 Arg2:T58	
R26	Experiences Arg1:T44 Arg2:T14	
T59	Observation 648 658	dispuestos
#46	AnnotatorNotes T59	C0600109; Willing; Finding
R27	Overlap Arg1:T59 Arg2:T7	
T60	Observation 708 729	disponer de capacidad
#47	AnnotatorNotes T60	C1299581; Able (finding); Finding (?) | C1555472; Authorized; Finding (?)
R28	Overlap Arg1:T7 Arg2:T60	
R33	Overlap Arg1:T20 Arg2:T45	
R34	Overlap Arg1:T36 Arg2:T45	
R35	Used_for Arg1:T36 Arg2:T20	
T61	Result_or_Value 1100 1125	≤50 ng/dL (≤ 1.73 nmol/L)
R36	Has_Result_or_Value Arg1:T37 Arg2:T61	
T62	PROC 1137 1146	selección
#48	AnnotatorNotes T62	C0242802; Patient Selection; Research Activity
R37	Overlap Arg1:T37 Arg2:T62	
R38	Experiences Arg1:T50 Arg2:T24	
R39	Experiences Arg1:T50 Arg2:T25	
R40	Has_Dose_or_Strength Arg1:T24 Arg2:T43	
R41	Has_Dose_or_Strength Arg1:T25 Arg2:T43	
R42	Has_Duration_or_Interval Arg1:T24 Arg2:T51	
R43	Has_Duration_or_Interval Arg1:T25 Arg2:T51	
R44	Before Arg1:T43 Arg2:T23	
T63	CONC 1388 1399	inscripción
#49	AnnotatorNotes T63	C2985881; Study Registration Date; Temporal Concept (?)
R45	Overlap Arg1:T27 Arg2:T63	
R46	Overlap Arg1:T26 Arg2:T63	
T64	Quantifier_or_Qualifier 1418 1432	mínimo de tres
T65	Observation 1433 1459	valores del PSA en aumento
#50	AnnotatorNotes T65	C0178415; Raised prostate specific antigen; Finding
R47	Has_Quantifier_or_Qualifier Arg1:T65 Arg2:T64	
R50	Has_Duration_or_Interval Arg1:T28 Arg2:T52	
R51	Has_Duration_or_Interval Arg1:T38 Arg2:T52	
R52	Has_Duration_or_Interval Arg1:T30 Arg2:T52	
R53	Overlap Arg1:T15 Arg2:T48	
R54	Overlap Arg1:T15 Arg2:T19	
R9	Before Arg1:T10 Arg2:T8	
#51	AnnotatorNotes T45	C0521116; Current (present time); Temporal Concept
A8	Experiencer T50 Patient
A9	Experiencer T40 Patient
A10	Experiencer T42 Patient
A11	Experiencer T44 Patient
A12	Assertion T24 Hypothetical
A13	Assertion T25 Hypothetical
R10	Has_Result_or_Value Arg1:T28 Arg2:T65	
